IO Biotech
IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.
IO Biotech has raised €127M across 1 funding round from 1 investor, most recently a Series B round in Jan 2021. Based in Copenhagen, Denmark; founded 2014; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€127M
€127,000,000
Funding rounds
1
Investors
1
distinct backers
Active since
2021-01
latest 2021-01
Funding by year
EUR raised per yearIO Biotech — funding by year — interactive chart.
Data table
| IO Biotech — funding by year | |
|---|---|
| 2021 | €127M |
Signals
High confidenceRaise-next likelihood9
base rate 48% for Series B
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-01-13 | Series B | €127M | HBM Healthcare Investments | View deal → |
Investors
1Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Oura Health€779MFinland · Healthtech
Global coverage: FundingData